Rucaparib resistance treatment

Rucaparib (Rucaparib) is aPARP inhibitor used to treat ovarian cancer andcastration-resistant prostate cancer. However, drug resistance is a problem that may arise, resulting in a drug becoming less effective against tumor cells. By establishing a drug resistance model and studying the resistance mechanism of rucapanib, we can better understand the development process of drug resistance. This will help identify new treatment strategies.

Testing patients for gene mutations, especiallyBRCA gene mutations, can help determine whether drug resistance exists. Based on the test results, the doctor can adjust the treatment plan. Rucaparib's strategy of combining multiple drugs may improve treatment efficacy and reduce the occurrence of drug resistance. For example, combining other chemotherapy drugs or immunotherapies may produce a synergistic effect. After resistance develops, rucapanib may need to be rotated with other PARP inhibitors. Different PARP inhibitors have different mechanisms of action and may have different effects on drug-resistant cells. According to the patient's individual situation and tumor characteristics,Since everyone has a different body constitution and different drug resistance reactions, please inform your doctor in time if you feel unwell.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).